Mustang Bio Announces First Data From Ongoing Multicenter Phase 1/2 Clinical Trial Evaluating MB-106 CAR-T Cell Therapy; Iniital Data Show Clinical Responses From Four Of Four Indolent Lymphoma Patients
Portfolio Pulse from Benzinga Newsdesk
Mustang Bio has announced initial data from its ongoing multicenter Phase 1/2 clinical trial evaluating MB-106 CAR-T cell therapy. The data shows clinical responses from all four indolent lymphoma patients involved in the trial.
August 16, 2023 | 12:03 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Mustang Bio's ongoing clinical trial for MB-106 CAR-T cell therapy has shown positive initial results, which could potentially boost the company's stock in the short term.
The positive initial results from the clinical trial of Mustang Bio's MB-106 CAR-T cell therapy indicate a successful development of the product. This could potentially lead to regulatory approval and commercialization, which would likely increase the company's revenues and, consequently, its stock price.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100